Failure of integrin inhibitors in clinical trials can be avoided by redesigning the chemical conformation of these proteins, as shown by a study led by Timothy Springer, a professor in the Department of Biological Chemistry and Molecular Pharmacology at Boston Children's Hospital, and one of the winners of the 2022 Albert Lasker Basic Medical Research Award.